Developing a Range of SVP-Enabled Candidates for Rare and Serious Diseases

Anti-Drug Antibody (ADA) Mitigation Programs
Selecta is developing a range of product candidates for patients with rare and serious diseases that utilize SVP-Rapamycin, the company's proprietary immune tolerance agent, to prevent the formation of ADAs that might otherwise compromise the medication's efficacy and safety.
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Licensee
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
plus-minus
SEL-212 is a monthly treatment consisting of pegsiticase, a potent uric acid lowering uricase enzyme, co-administered with SVP-Rapamycin to prevent ADAs. In clinical trials, this product candidate has shown an ability to significantly lower serum uric acid to levels conducive to rapid tophi dissolution and the reduction of flares and other symptoms.  learn more >
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
plus-minus
SEL-403 consists of a recombinant immunotoxin candidate (LMB-100), which is in Phase 1a mesothelioma and pancreatic cancer clinical trials, co-administered with SVP-Rapamycin to prevent ADAs. The National Cancer Institute licensed LMB-100 patents to Selecta, and Selecta and NCI are now preparing a Phase 1b clinical trial to assess the ability for mesothelioma patients to receive multiple treatment cycles of SEL-403.  learn more >
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
plus-minus
Selecta's lead gene therapy candidate, SEL-302, aims to substantially improve the quality of life for patients with MMA, a rare and severe inborn error of metabolism. This product candidate utilizes Anc80, a proprietary gene therapy vector, co-administered with SVP-Rapamycin to enable for the first time repeated doses of gene therapy and prevent liver toxicity caused by cellular immune responses.  learn more >
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
plus-minus
SEL-313 is being developed as a potential treatment for OTC, an inborn error of metabolism that impacts 15,000 to 60,000 people worldwide. This product candidate utilizes an adeno associated virus (AAV)-based gene therapy, co-administered with SVP-Rapamycin to enable repeated doses of gene therapy and prevent liver toxicity caused by cellular immune responses.  learn more >
Hemophilia A - Gene Therapy
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
Spark Therapeutics
Licensee: Spark Therapeutics
plus-minus
In December 2016, Selecta signed a license agreement providing Spark Therapeutics with exclusive worldwide rights to Selecta's SVP platform technology for co-administration with hemophilia A gene therapies. 
Immune Stimulation Programs
Selecta is utilizing non-dilutive funding to develop additional product candidates that leverage the company's proprietary Synthetic Vaccine Particles (SVP™) technology to stimulate an immune response.
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Collaboration
Smoking Cessation & Relapse Prevention
SELA-070
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
National Institutes of Health (NIH)
Collaboration: National Institutes of Health (NIH)
plus-minus
SELA-070 is in a Phase 1 clinical trial with funding from the National Institute on Drug Abuse. The program utilizes SVP to trigger the production of a high level of anti-nicotine antibodies that bind to the nicotine inhaled by smokers, thus preventing nicotine from crossing the blood-brain barrier and triggering an addictive response.
HPV-Associated Cancer
SEL-701
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
Skolkovo Foundation
Collaboration: Skolkovo Foundation
plus-minus
SEL-701 is an SVP-enabled immunotherapy candidate that is intended to harness the body's 'killer' immune cells, known as cytolytic T-lymphocytes (CTL), to attack cervical and head and neck cancers caused by infections with Human Papilloma Virus (HPV). This product candidate is being developed under funding from Skolkovo Foundation.
Back to Top